Do analysts rate LGVN or ETHZ?

Longeveron presently has a consensus price target of $5.50, indicating a potential upside of 696.52%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than Flag Ship Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer VRCA or LGVN?

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Longeveron's average media sentiment score of 0.84 beat Verrica Pharmaceuticals' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longeveron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PMN or LGVN?

In the previous week, Promis Neurosciences and Promis Neurosciences both had 1 articles in the media. Longeveron's average media sentiment score of 0.84 beat Promis Neurosciences' score of 0.50 indicating that Longeveron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Longeveron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SXTC or LGVN?

Longeveron has a consensus target price of $5.50, indicating a potential upside of 696.52%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than China SXT Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable earnings & valuation, SXTC or LGVN?

China SXT Pharmaceuticals has higher earnings, but lower revenue than Longeveron. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 82.28 -$3.30M N/A N/A Longeveron $1.20M 17.92 -$22.70M -$1.13 N/A

Does the media favor LGVN or ANIX?

In the previous week, Anixa Biosciences had 2 more articles in the media than Longeveron. MarketBeat recorded 3 mentions for Anixa Biosciences and 1 mentions for Longeveron. Longeveron's average media sentiment score of 0.84 beat Anixa Biosciences' score of -0.32 indicating that Longeveron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Longeveron (LGVN) Competitors

$0.69 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.70 +0.01 (+2.10%)

As of 07/2/2026 07:47 PM Eastern

Compare

LGVN vs. ETHZ, VRCA, PMN, SXTC, and ANIX

Should you buy Longeveron stock or one of its competitors? MarketBeat compares Longeveron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Longeveron include Flag Ship Acquisition (ETHZ), Verrica Pharmaceuticals (VRCA), Promis Neurosciences (PMN), China SXT Pharmaceuticals (SXTC), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry.

How does Longeveron compare to Flag Ship Acquisition?

Longeveron (NASDAQ:LGVN) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

In the previous week, Longeveron had 1 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 1 mentions for Longeveron and 0 mentions for Flag Ship Acquisition. Longeveron's average media sentiment score of 0.84 beat Flag Ship Acquisition's score of 0.00 indicating that Longeveron is being referred to more favorably in the media.

Company	Overall Sentiment
Longeveron	Positive
Flag Ship Acquisition	Neutral

Flag Ship Acquisition has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	17.92	-$22.70M	-$1.13	N/A
Flag Ship Acquisition	$4.11M	27.85	-$6.17M	-$159.65	N/A

Flag Ship Acquisition has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Flag Ship Acquisition's return on equity of -185.71% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,844.49%	-202.41%	-140.67%
Flag Ship Acquisition	N/A	-185.71%	-83.12%

Longeveron has a beta of -0.35, indicating that its share price is 135% less volatile than the broader market. Comparatively, Flag Ship Acquisition has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

Longeveron presently has a consensus price target of $5.50, indicating a potential upside of 696.52%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than Flag Ship Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.0% of Longeveron shares are held by institutional investors. Comparatively, 4.1% of Flag Ship Acquisition shares are held by institutional investors. 7.4% of Longeveron shares are held by company insiders. Comparatively, 15.1% of Flag Ship Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Flag Ship Acquisition beats Longeveron on 9 of the 16 factors compared between the two stocks.

How does Longeveron compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Verrica Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market.

Verrica Pharmaceuticals currently has a consensus target price of $14.50, indicating a potential upside of 136.16%. Longeveron has a consensus target price of $5.50, indicating a potential upside of 696.52%. Given Longeveron's higher possible upside, analysts clearly believe Longeveron is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Longeveron's average media sentiment score of 0.84 beat Verrica Pharmaceuticals' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Longeveron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verrica Pharmaceuticals has higher revenue and earnings than Longeveron. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$37.16M	2.84	-$17.89M	-$1.03	N/A
Longeveron	$1.20M	17.92	-$22.70M	-$1.13	N/A

Verrica Pharmaceuticals has a net margin of -47.97% compared to Longeveron's net margin of -1,844.49%. Longeveron's return on equity of -202.41% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Longeveron	-1,844.49%	-202.41%	-140.67%

Summary

Verrica Pharmaceuticals beats Longeveron on 8 of the 13 factors compared between the two stocks.

How does Longeveron compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, Promis Neurosciences and Promis Neurosciences both had 1 articles in the media. Longeveron's average media sentiment score of 0.84 beat Promis Neurosciences' score of 0.50 indicating that Longeveron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Longeveron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Promis Neurosciences has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Longeveron's return on equity of -202.41% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Longeveron	-1,844.49%	-202.41%	-140.67%

Promis Neurosciences has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, indicating that its share price is 135% less volatile than the broader market.

Promis Neurosciences presently has a consensus price target of $26.50, indicating a potential upside of 98.50%. Longeveron has a consensus price target of $5.50, indicating a potential upside of 696.52%. Given Longeveron's higher probable upside, analysts clearly believe Longeveron is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Longeveron has higher revenue and earnings than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Longeveron	$1.20M	17.92	-$22.70M	-$1.13	N/A

Summary

Longeveron beats Promis Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Longeveron compare to China SXT Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Comparatively, 7.4% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, China SXT Pharmaceuticals and China SXT Pharmaceuticals both had 1 articles in the media. China SXT Pharmaceuticals' average media sentiment score of 1.38 beat Longeveron's score of 0.84 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
China SXT Pharmaceuticals	Positive
Longeveron	Positive

China SXT Pharmaceuticals has higher earnings, but lower revenue than Longeveron.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	82.28	-$3.30M	N/A	N/A
Longeveron	$1.20M	17.92	-$22.70M	-$1.13	N/A

China SXT Pharmaceuticals has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, indicating that its stock price is 135% less volatile than the broader market.

China SXT Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. China SXT Pharmaceuticals' return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Longeveron	-1,844.49%	-202.41%	-140.67%

Longeveron has a consensus target price of $5.50, indicating a potential upside of 696.52%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than China SXT Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

China SXT Pharmaceuticals beats Longeveron on 7 of the 13 factors compared between the two stocks.

How does Longeveron compare to Anixa Biosciences?

Longeveron (NASDAQ:LGVN) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Longeveron presently has a consensus target price of $5.50, suggesting a potential upside of 696.52%. Anixa Biosciences has a consensus target price of $8.50, suggesting a potential upside of 159.94%. Given Longeveron's higher probable upside, equities analysts plainly believe Longeveron is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Anixa Biosciences had 2 more articles in the media than Longeveron. MarketBeat recorded 3 mentions for Anixa Biosciences and 1 mentions for Longeveron. Longeveron's average media sentiment score of 0.84 beat Anixa Biosciences' score of -0.32 indicating that Longeveron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 7.4% of Longeveron shares are owned by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Anixa Biosciences has lower revenue, but higher earnings than Longeveron. Anixa Biosciences is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	17.92	-$22.70M	-$1.13	N/A
Anixa Biosciences	$210K	529.74	-$10.93M	-$0.31	N/A

Anixa Biosciences has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Anixa Biosciences' return on equity of -71.12% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,844.49%	-202.41%	-140.67%
Anixa Biosciences	N/A	-71.12%	-62.88%

Longeveron has a beta of -0.35, indicating that its stock price is 135% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Summary

Anixa Biosciences beats Longeveron on 12 of the 16 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGVN vs. The Competition

Export

Metric	Longeveron	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.51M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.61	21.61	28.02	24.70
Price / Sales	17.92	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	2.76	8.66	10.96	6.46
Net Income	-$22.70M	$23.81M	$3.57B	$337.01M
7 Day Performance	-3.70%	3.39%	2.12%	1.69%
1 Month Performance	-5.41%	10.81%	5.25%	3.81%
1 Year Performance	-47.49%	62.61%	33.29%	23.90%

Longeveron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGVN Longeveron	2.8856 of 5 stars	$0.69 flat	$5.50 +696.5%	-47.5%	$21.51M	$1.20M	N/A	20	Gap Up
ETHZ Flag Ship Acquisition	N/A	$5.16 +2.2%	N/A	N/A	$98.10M	$4.11M	N/A	7	Gap Up
VRCA Verrica Pharmaceuticals	2.5017 of 5 stars	$5.65 +0.2%	$14.50 +156.6%	-10.8%	$97.06M	$37.16M	N/A	40	Gap Down
PMN Promis Neurosciences	3.7113 of 5 stars	$10.69 +0.1%	$26.50 +147.9%	+15.3%	$95.89M	N/A	N/A	5	Analyst Forecast Gap Up
SXTC China SXT Pharmaceuticals	0.7135 of 5 stars	$2.48 +3.8%	N/A	-99.1%	$94.78M	$1.54M	N/A	90	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGVN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Longeveron (LGVN) Competitors

LGVN vs. ETHZ, VRCA, PMN, SXTC, and ANIX

How does Longeveron compare to Flag Ship Acquisition?

Summary

How does Longeveron compare to Verrica Pharmaceuticals?

Summary

How does Longeveron compare to Promis Neurosciences?

Summary

How does Longeveron compare to China SXT Pharmaceuticals?

Summary

How does Longeveron compare to Anixa Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Longeveron (LGVN) Competitors

LGVN vs. ETHZ, VRCA, PMN, SXTC, and ANIX

How does Longeveron compare to Flag Ship Acquisition?

Does the media refer more to LGVN or ETHZ?

Which has preferable valuation and earnings, LGVN or ETHZ?

Is LGVN or ETHZ more profitable?

Which has more risk and volatility, LGVN or ETHZ?

Do analysts rate LGVN or ETHZ?

Do institutionals & insiders believe in LGVN or ETHZ?

Summary

How does Longeveron compare to Verrica Pharmaceuticals?

Do insiders & institutionals believe in VRCA or LGVN?

Which has more volatility & risk, VRCA or LGVN?

Do analysts prefer VRCA or LGVN?

Does the media prefer VRCA or LGVN?

Which has better earnings and valuation, VRCA or LGVN?

Is VRCA or LGVN more profitable?

Summary

How does Longeveron compare to Promis Neurosciences?

Does the media prefer PMN or LGVN?

Do insiders and institutionals believe in PMN or LGVN?

Is PMN or LGVN more profitable?

Which has more risk and volatility, PMN or LGVN?

Do analysts prefer PMN or LGVN?

Which has higher valuation and earnings, PMN or LGVN?

Summary

How does Longeveron compare to China SXT Pharmaceuticals?

Do insiders & institutionals believe in SXTC or LGVN?

Does the media favor SXTC or LGVN?

Which has preferable earnings & valuation, SXTC or LGVN?

Which has more risk & volatility, SXTC or LGVN?

Is SXTC or LGVN more profitable?

Do analysts prefer SXTC or LGVN?

Summary

How does Longeveron compare to Anixa Biosciences?

Do analysts rate LGVN or ANIX?

Does the media favor LGVN or ANIX?

Do insiders and institutionals hold more shares of LGVN or ANIX?

Which has better earnings & valuation, LGVN or ANIX?

Is LGVN or ANIX more profitable?

Which has more risk and volatility, LGVN or ANIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools